T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma
First-in-Human Phase 1 Study of a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager (TCE), BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma
Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma
Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors
Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors
A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy
A Novel Dual CAB Nectin-4 x CD3 Bispecific Antibody Targeting Solid Tumors
A Novel Conditionally Active Bispecific HER2 X CD-3 T Cell Engager Targeting Solid Tumors
A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors
Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging
